Search results for "Biosimilars"

Article 3rd BioProcessing Asia Preview: Q&A with John Curling
The program always covers the entire biopharmaceutical spectrum from antibodies and blood plasma products to vaccines as well as biosimilars development. BioProcessing Asia also differentiates itself …

Article Process Development: What May Lie Ahead in 2018?
2018 is shaping up to be an interesting year in the world of biopharmaceuticals. What have 2017 developments taught us, and what may lie ahead for biopharmaceutical drug developers and process engin…

Article From Darwin to Recombinant Fc Multimers
no biosimilars • Continued innovation, investment and progress To ensure future vitality of the industry, Perkins talked about the importance of securing plasma supply, donor and patient safet…

Article Witnessing Major Growth in Next-Generation Antibodies
Including next-gen antibodies in pharma pipelines is considered essential for future success. By Cynthia A. Challener Next-generation antibodies are designed to be more specific and are ofte…

Article Speed and Flexibility Are Dual Goals for Biopharma Operations
Bioprocessing facilities, equipment, and materials, as well as strategies to improve biopharmaceutical development and manufacturing, were featured at INTERPHEX 2017, held in March in New York City.…

Article Single-use Bioreactors Have Reached the Big Time
…ocesses, the growth of biologics targeting smaller patient populations and the expanding demand for biosimilars in emerging markets has meant that total output needs now fit within the capable produc…

Article Make buffer preparation more time and cost efficient with inline conditioning
Simplify Buffer Preparation The volume and number of buffers for a typical downstream process can be considerable. Preparation of these buffers is a challenge that in-line conditioning can o…

Article A Q&A on Bioprocessing Trends and Technologies at INTERPHEX 2016
One sign of progress was the opening of a JHL Biotech flexible manufacturing facility in Wuhan, China on May 10, 2016, for the manufacture of biosimilars and monoclonal antibodies (mAbs). The facility…

Article Continuous Processing for the Production of Biopharmaceuticals
With the growing demand for biosimilars and an ever-increasing pressure for reduction in manufacturing costs, the biotech industry seems to exhibit a flourishing interest in the development of continu…

Poster Modes of controlling charge variant distribution in Mab production
The characteristics of a biological drug, for example, charge variant profile, are determined to a large extent by the upstream expression system and conditions, but can also be influenced by the pu…

Previous PageNext Page